Head-Image

News

Successful Series-A financing for Leon-Nanodrugs – TVM Capital brings Quebec investors on board

04.08.2015



TVM Capital Life Science, based in Munich and Montreal, leads an international syndicate of investors. Other participants are Signet Healthcare Partners (USA), LifeCare Partners (CH), CD Venture (D), Albany Private Equity Holding (AUS), and an unnamed Family Office from Germany. Another Chinese investor is expected to finance another 3 M euros later in the process – bringing the overall financing volume of this series to 21.5 M euros.

With this fresh capital, Leon Nanodrugs will develop their services range and start first profitable development partnerships with pharmaceutical companies. The Munich-based company was founded in 2011 and offers a technological platform with which low-molecular and biological substances are reformulated in nanoparticles for oral or parenteral medication. The surface-to-volume rate being better than for classical drugs, this enables better bio-availability and solubility of the substances, according to Leon Nanodrugs. Reformulation of existing substances is also said to be a way to extend the life-cycle of patent-protected drugs.

About TVM Capital Life Science
TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, which results from its partnership with the American pharmaceutical company Eli Lilly & Co and Teralys, a Quebec venture capital group created by Investissement Québec, Caisse des Dépôts and Fonds de solidarité FTQ. www.tvm-lifescience.com

Source & more: www.bio-m.org,
www.b3cnewswire.com